Patents by Inventor Jutta Schreiner

Jutta Schreiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)
    Patent number: 10900979
    Abstract: The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: January 26, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS 13 ACTIVITY
    Publication number: 20190145989
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: January 16, 2019
    Publication date: May 16, 2019
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Katalin VARADI, Hanspeter ROTTENSTEINER, Peter TURECEK, Hans-Peter SCHWARZ, Jutta SCHREINER
  • Methods of measuring adamts 13 activity
    Patent number: 10209263
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: February 19, 2019
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS 13 ACTIVITY
    Publication number: 20170153255
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: November 7, 2016
    Publication date: June 1, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin VARADI, Hanspeter ROTTENSTEINER, Peter TURECEK, Hans-Peter SCHWARZ, Jutta SCHREINER
  • Methods of measuring ADAMTS 13 activity
    Patent number: 9488651
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 8, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20160033506
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: November 20, 2014
    Publication date: February 4, 2016
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor
    Patent number: 9110085
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 18, 2015
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20140154709
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: November 12, 2013
    Publication date: June 5, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONSL INC.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Method for testing treatment of ADAMTS13 deficiency
    Patent number: 8623612
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 7, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20130252263
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
    Patent number: 8415114
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: April 9, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20100143957
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: December 3, 2009
    Publication date: June 10, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner